Seqirus has public health protection at its core, which reflects the promise of our parent company CSL Limited (ASX:CSL), founded in 1916 to save lives and protect the health of people. Our first true test came with the Spanish Influenza Pandemic in 1918 and we have been committed to the fight against influenza ever since. As one of the largest influenza vaccine providers in the world, Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness. Seqirus operates state-of-the-art production facilities in the U.S., the UK and Australia, manufactures influenza vaccines using both egg-based and cell-based technologies and has a globally integrated supply chain. It has a rich R&D pipeline, a broad portfolio of differentiated products and a commercial presence in more than 20 countries. To learn more visit